D.R. Horton, Inc. DHI
Composite 53/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 30/100 — a moderate mark against it.
Balance-sheet strength ranks 79/100 — a strong point in its favour. Valuation ranks 66/100 — a moderate point in its favour.
Momentum ranks 30/100 — a moderate mark against it. Growth ranks 34/100 — a moderate mark against it. Quality ranks 48/100 — a slight mark against it.
What the company does D.R. Horton, Inc. (DHI) is a U.S. homebuilder operating in 36 states across 126 markets, offering single-family detached homes, townhomes, and rental properties. It also provides mortgage financing, title services, and water-related assets. The company targets homebuyers and investors, with a focus on land acquisition, development, and construction.
Key financials DHI reports ROE 12.6%, ROA 6.9%, and ROCE 12.1%, with gross/operating/net margins at 21.3%/13.0%/9.2%. Revenue and EPS growth are negative at -6.9% and -19.4%, respectively. Debt/Equity is 0.29, and the current ratio stands at 6.01, indicating liquidity strength.
Stock health The stock shows weak momentum, with 3m/6m/12m declines of -4.14%/-6.81%/-15.58% and a -22.48% drawdown from its 52-week high. RSI(14) is 41.40, suggesting neutral-to-bearish short-term sentiment. Sidera’s overall score is 52.2, with weak quality (48.5) and growth (33.3).
Price vs fair value DHI trades at a **discount of 15.20%** versus the analyst mean target of 162.92. - Rising crude oil and bond yields weighed on stocks (2026-08-31). - Geopolitical risks further pressured equities (2026-08-31). - Berkshire’s homebuilder purchase in the same month as JPMorgan’s $750B housing commitment may signal sector interest (2026-08-31).
Looking forward Forward P/E (12.39) and PEG (1.02) suggest moderate valuation, while EV/EBITDA (11.69) and FCF yield (6.1%) indicate potential attractiveness. Weak growth scores and momentum may cap near-term upside despite the valuation discount.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.